{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T10:28:48Z","timestamp":1648636128267},"reference-count":0,"publisher":"Canadian Science Publishing","issue":"4","license":[{"start":{"date-parts":[[1984,4,1]],"date-time":"1984-04-01T00:00:00Z","timestamp":449625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[1984,4,1]]},"abstract":"<jats:p> Radiolabelled acetylsalicylic acid (ASA) and salicylic acid (SA) were given intravenously to four near-term ewes and their occurrence in both maternal and fetal plasma was ascertained using a specific thin-layer chromatographic analysis procedure. Findings proved that ASA and SA cross the placental barrier and reach distribution equilibrium about 40\u2002min after salicylate administration. The equilibrium plasma fetal\/maternal ratio for both salicylates averaged 0.4. Plasma concentrations of the two compounds in the mother and the fetus accorded with a two-compartment model having unusually large mean estimates (54 and 39\u2002L) for the tissue distribution space of ASA and SA, respectively. Furthermore, the mean SA clearance in the ewe (358\u2002mL\u2219min<jats:sup>\u22121<\/jats:sup>) was much greater than that reported in man, while the mean ASA clearance (764\u2002mL\u2219min<jats:sup>\u22121<\/jats:sup>) was similar. Since ASA is an irreversible inhibitor of arachidonate cyclooxygenase, our findings reassert the need for caution in the use of the drug during pregnancy. <\/jats:p>","DOI":"10.1139\/y84-070","type":"journal-article","created":{"date-parts":[[2011,4,23]],"date-time":"2011-04-23T20:51:39Z","timestamp":1303591899000},"page":"441-445","source":"Crossref","is-referenced-by-count":1,"title":["Placental drug transfer in near-term ewes: acetylsalicylic and salicylic acid"],"prefix":"10.1139","volume":"62","author":[{"given":"J. J.","family":"Thiessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. B.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Coceani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Olley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/pdf\/10.1139\/y84-070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T16:22:46Z","timestamp":1578241366000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/10.1139\/y84-070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,4,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1984,4,1]]}},"alternative-id":["10.1139\/y84-070"],"URL":"https:\/\/doi.org\/10.1139\/y84-070","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,4,1]]}}}